liraglutide + phentermine + semaglutide

This is a combination of three pharmaceutical agents—liraglutide, phentermine, and semaglutide—each with distinct mechanisms for weight management. Liraglutide and semaglutide are both glucagon-like peptide-1 (GLP-1) receptor agonists that mimic the action of endogenous GLP-1 to increase insulin secretion, suppress appetite, slow gastric emptying, and promote satiety. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine in the brain. While each drug individually is approved for obesity or weight loss management (and diabetes in some cases), there is no evidence that this specific triple combination has been developed as a single pharmaceutical product or studied in clinical trials. The use of these drugs together would be considered off-label and should only be done under medical supervision due to potential additive side effects and lack of established safety data[1][2][4][6].